Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
World J Plast Surg ; 10(1): 78-84, 2021 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-33833958

RESUMO

BACKGROUND: Radiotherapy as an adjuvant therapy to surgical resection has shown variable rates of recurrence treating earlobe keloids. The purpose of this study was to describe our experience with surgical excision followed by high-dose-rate brachytherapy and present our outcomes after 24 months of follow-up. METHODS: Retrospective chart of 14 patients with 14 earlobe keloids treated with surgical excision followed by high-dose-rate brachytherapy, between January 2015 and May 2016 were enrolled. Database included demographics, Fitzpatrick skin type, laterality, lesion size, and follow-up visits information. Outcomes were assessed in terms of keloid recurrence rates, complications, and patient subjective aesthetical result satisfaction after 24 months of follow-up. RESULTS: All procedures were completed without complications. Three patients experienced keloid recurrence after 6 (14.28%) and 12 months (7.14%). Three patients experienced mild signs of self-limited post-radiation dermatitis. Self-assessment of aesthetical result was considered "very good" in 71.43% of patients. CONCLUSION: Surgical excision followed by high-dose-rate brachytherapy is secure and effective to treat earlobe keloids, and can be considered a first line combined treatment. Larger clinical trials comparing different irradiation protocols are still needed.

2.
Lasers Surg Med ; 53(4): 468-475, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-32827340

RESUMO

BACKGROUND AND OBJECTIVE: Lasers have a favorable synergistic effect when combined with other modalities of treatment against keloids. Different types of lasers have been used with triamcinolone infiltration, resulting in promising success rates. The purpose of this study is to describe our first experience treating earlobe keloids with 980 nm laser diode excision followed by triamcinolone infiltration and present our outcomes after 24 months of follow-up. STUDY DESIGN/MATERIALS AND METHODS: A retrospective chart review of 11 patients with 14 earlobe keloids treated with excision using a 980 nm laser diode followed by triamcinolone acetonide infiltration, between January 2015 and May 2016. Database included demographics, Fitzpatrick skin type, laterality, lesion size, and postoperative visits information. Outcomes were assessed in terms of keloid recurrence rates, complications, and patient subjective aesthetical result satisfaction after 24 months of follow-up. RESULTS: All procedures were technically completed, and follow-up accomplished without attrition. One (7.14%) patient experienced keloid recurrence after the third month. Four (28.57%) patients experienced early wound dehiscence, successfully treated with debridement and re-suture. Self-assessment of aesthetical result was considered "very good" in 64.28% of patients. CONCLUSION: Surgical excision with 980 nm laser diode followed by triamcinolone infiltration is well-tolerated and shows favorable results treating earlobe keloids, and can be considered a first-line treatment. Comparison between different types of lasers and control groups in large clinical trials is warranted in order to obtain strong clinical evidence for clear indications and recommendations. Lasers Surg. Med. © 2020 Wiley Periodicals LLC.


Assuntos
Queloide , Humanos , Queloide/tratamento farmacológico , Queloide/cirurgia , Lasers Semicondutores/uso terapêutico , Recidiva , Estudos Retrospectivos , Resultado do Tratamento , Triancinolona Acetonida
3.
Rev. Fac. Med. (Caracas) ; 31(1): 45-51, jun. 2008. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-631539

RESUMO

La hipertensión arterial afecta aproximadamente 50 millones de individuos en Estados Unidos de América y un mil millones de individuos en el resto del mundo, afectando de un 15 por ciento a 30 por ciento de la población mundial, y es uno de los factores predictivos de enfermedad cardiovascular más importantes, por lo tanto su control es indispensable. Este estudio comparó la acción antihipertensiva de la combinación hidroclorotiazida/bisoprolol con la combinación enalapril/amlodipina en pacientes con diagnóstico de hipertensión arterial no controlada. Métodos: Se realizó un ensayo clínico controlado aleatorizado en pacientes hipertensos con edades comprendidas entre 30 y 65 años con diagnóstico de hipertensión arterial con o sin tratamiento. Fueron distribuidos en dos grupos de 10 pacientes; uno recibió tratamiento con hidroclorotiazida/bisoprolol y el otro con enalapril/amlodipina bajo un protocolo de ajuste de dosis según metas de PA para 4 semanas. Resultados: Ambas combinaciones redujeron significativamente los valores de presión arterial a las 4 semanas (P=< 0,0001). Sin embargo, el efecto antihipertensivo de la combinación hidroclorotiazida/Bisoprolol fue superior para la reducción de la presión diastólica (P= 0,025), y el alcance de la meta de 120/70 mmHg (90 por ciento vs. 50 por ciento). Conclusión: La utilización de la combinación hidroclorotiazida / bisoprolol tiene mayor número de beneficios que los observados con la combinación enalapril / amlodipina en el manejo de la hipertensión arterial no controlada


The High Blood Pressure affects around 50 millions people in the EE.UU of America and a thousand million people all around the world, affecting 15 percent to 30 percent of the world’s population, and is one of the most important predictive factors of cardiovascular disease; therefore its control is essential. This study compared the antihypertensive action of the combination Hydrochlorothiazide/Bisoprolol with the combination Enalapril/Amlodipine in patients with uncontrolled High Blood Pressure diagnosis. Methods: We performed a randomized, controlled, clinical essay, in patients with High Blood Pressure between 30 and 65 years old, with High Blood Pressure previous diagnosis under treatment or not. They were distributed into two groups of 10 patients each one; one group received Hydrochlorothiazide/Bisoprolol, and the other one, received Enalapril/Amlodipine under a standardized regimen of titration according to BP goals during 4 weeks. Results: Both combinations reduced significantly BP values at 4 weeks of treatment (P= <0.0001). However, the antihypertensive effect of the combination Hydrochlorothiazide/Bisoprolol was superior in the reduction of diastolic values of BP (P= 0,025), and the reach of the 120/70 mmHg goal (90 percent vs. 50 percent). Conclusions: the use of the combination Hydrochlorothiazide/Bisoprolol is related to a higher number of benefits than the use of the combination Enalapril/Amlodipine in the management of patients with uncontrolled High Blood Pressure diagnosis


Assuntos
Humanos , Bisoprolol/uso terapêutico , Enalapril/uso terapêutico , Hidroclorotiazida/uso terapêutico , Hipertensão/tratamento farmacológico , Hipertensão/terapia , Pressão Sanguínea
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA